Opportunity Information: Apply for RFA CA 10 016
Apply for RFA CA 10 016
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Clinical Proteomic Technologies for Cancer Initiative (CPTC) Proteome Characterization Centers (U24)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.396 Cancer Biology Research 93.397 Cancer Centers Support Grants.
- This funding opportunity was created on Jun 25, 2010 and posted on Jun 25, 2010.
- Applicants must submit their applications by Sep 29, 2010. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Others (see text field entitled Additional Information on Eligibility for clarification) State governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments City or township governments Public and State controlled institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Clinical Proteomic Technologies for Cancer Initiative (CPTC) Proteome Characterization Centers (U24) funding opportunity (RFA-CA-10-016) is a National Institutes of Health, National Cancer Institute announcement designed to expand and solidify a national, team-based infrastructure for cancer proteomics. The core aim is to build directly on the standards, technologies, standard operating procedures, and end-to-end workflows that CPTC previously established to make protein identification and quantification more reliable and reproducible across laboratories. In practical terms, the program is meant to move proteomics from one-off, lab-specific efforts into a coordinated, cross-center system where methods are harmonized, results are comparable, and large-scale cancer proteome characterization can be executed with consistency.
The FOA calls for the creation of a multidisciplinary, collaborative network of Proteome Characterization Centers (PCCs). These centers are expected to work together across institutions and disciplines, not as isolated projects, using shared protocols and coordinated plans. A key feature is the strong connection to cancer genomics resources, particularly large programs like The Cancer Genome Atlas (TCGA) and similar initiatives. The centers are expected to leverage existing genomics datasets and selected biospecimens tied to those datasets to systematically define the functional cancer proteome, meaning the actual protein-level consequences of genomic alterations in tumors. This emphasizes the idea that while genomes indicate what could happen, proteomic measurements help determine what is happening biologically in cells and tissues, including pathway activity, protein expression changes, and potentially clinically relevant protein modifications.
Within that larger scientific mission, the opportunity highlights three tightly linked outcomes. First, the PCC network should generate a more comprehensive and systematic understanding of how genomic changes in cancer translate into protein-level changes, producing a functional view of tumor biology grounded in measured proteins and peptides. Second, the centers should discover and verify candidate protein and peptide biomarkers, with an emphasis on moving beyond initial discovery toward verification steps that strengthen confidence in findings and improve their utility for downstream clinical research. Third, the work is expected to drive continued development of proteomic technologies themselves, meaning that method development and technology refinement are not side benefits but explicit expectations, especially when new analytical challenges arise from large, complex, clinically annotated sample sets.
Funding is provided through the NIH U24 cooperative agreement mechanism, which signals a substantial level of programmatic involvement and coordination with NIH/NCI compared with a standard investigator-initiated grant. A cooperative agreement is typically used when the sponsor anticipates active collaboration, shared governance, milestones, and coordinated deliverables across awardees, aligning well with the stated goal of creating a multi-center, interlocking network rather than a collection of independent awards.
The NCI projected support for 6 to 8 center awards. Total funding committed was approximately $15 million to $24 million in FY 2011, with an estimated $75 million to $120 million in total costs over the planned five-year project period. This scale reflects both the infrastructure-heavy nature of proteome characterization and the need for sustained, coordinated operations across multiple centers, including standardized processing, data generation, quality control, and integration with external genomics resources.
Eligibility is broad and includes many organization types, such as public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, and governmental entities at the state, county, and city/township level. The announcement also allows other eligible applicants such as certain federal agencies, non-U.S. (foreign) entities, and regional organizations, as described in the FOA’s eligibility details. The opportunity does not require cost sharing or matching.
Administratively, the announcement was posted June 25, 2010, with an original and current closing date of September 29, 2010, and an archive date of October 30, 2010. It is categorized as discretionary funding, uses the cooperative agreement instrument type, and aligns with several cancer-related CFDA areas including cancer cause and prevention research, detection and diagnosis research, cancer biology research, and cancer centers support grants. The full announcement and official instructions were made available through the NIH grants guide at the link provided in the notice.
FAQs: CPTC Proteome Characterization Centers (U24) - RFA-CA-10-016
What is this funding opportunity?
This is a National Institutes of Health (NIH), National Cancer Institute (NCI) funding opportunity announcement for the Clinical Proteomic Technologies for Cancer Initiative (CPTC) Proteome Characterization Centers (PCCs) using the U24 cooperative agreement mechanism (RFA-CA-10-016).
What is the overall purpose of the program?
The purpose is to expand and solidify a national, team-based infrastructure for cancer proteomics. The program is intended to move proteomics from isolated, lab-specific efforts into a coordinated, cross-center system where methods are harmonized, results are comparable, and large-scale cancer proteome characterization can be performed consistently.
What is CPTC trying to improve in cancer proteomics?
The initiative aims to make protein identification and quantification more reliable and reproducible across laboratories by building directly on CPTC-established standards, technologies, standard operating procedures (SOPs), and end-to-end workflows.
What types of awards does NCI plan to make under this FOA?
NCI projected support for approximately 6 to 8 center awards.
What mechanism is used (U24), and what does that imply?
The FOA uses an NIH U24 cooperative agreement. This implies substantial programmatic involvement and coordination with NIH/NCI compared with a standard investigator-initiated grant, typically including active collaboration, shared governance, milestones, and coordinated deliverables across awardees.
What is a Proteome Characterization Center (PCC) in this context?
A PCC is intended to be part of a multidisciplinary, collaborative network of centers working together across institutions and disciplines. The centers are expected to operate as a coordinated system rather than as isolated projects, using shared protocols and coordinated plans.
How are the centers expected to work together?
The FOA emphasizes a collaborative network with harmonized methods and coordinated plans so that results are comparable across centers and the overall effort functions as an interlocking, multi-center infrastructure.
How does this program connect proteomics with cancer genomics?
A key feature is a strong connection to cancer genomics resources, particularly large programs like The Cancer Genome Atlas (TCGA) and similar initiatives. The centers are expected to leverage existing genomics datasets and selected biospecimens linked to those datasets to help define the functional cancer proteome.
What does "functional cancer proteome" mean in the description?
It refers to systematically defining the protein-level consequences of genomic alterations in tumors. The concept highlighted is that genomes indicate what could happen, while proteomic measurements help determine what is happening biologically in cells and tissues, including pathway activity, protein expression changes, and potentially clinically relevant protein modifications.
What are the main expected outcomes of the PCC network?
The FOA highlights three tightly linked outcomes: (1) a more comprehensive and systematic understanding of how genomic changes translate into protein-level changes; (2) discovery and verification of candidate protein and peptide biomarkers, emphasizing verification beyond initial discovery; and (3) continued development and refinement of proteomic technologies, especially to address challenges from large, complex, clinically annotated sample sets.
Does the FOA focus only on biomarker discovery?
No. While biomarker work is included, the FOA explicitly emphasizes moving beyond initial discovery toward verification steps that strengthen confidence in candidate protein and peptide biomarkers and improve their usefulness for downstream clinical research.
Is technology development required or optional?
The description presents proteomic technology development and refinement as an explicit expectation of the program, not merely a secondary benefit, particularly when new analytical challenges arise from the scale and complexity of the samples and datasets.
What kinds of work does the funding support in practical terms?
The scale and infrastructure focus reflect sustained, coordinated operations across multiple centers, including standardized processing, data generation, quality control, and integration with external genomics resources.
How much funding is available?
NCI committed approximately $15 million to $24 million in FY 2011. The estimated total costs over the planned five-year project period were approximately $75 million to $120 million.
How long is the planned project period?
The planned project period described is five years.
Is cost sharing or matching required?
No cost sharing or matching is required for this opportunity.
Who is eligible to apply?
Eligibility is broad and includes public and private institutions of higher education, nonprofit organizations (including those with and without 501(c)(3) status), for-profit organizations other than small businesses, and governmental entities at the state, county, and city/township level. The FOA also allows other eligible applicants such as certain federal agencies, non-U.S. (foreign) entities, and regional organizations, as described in the FOA eligibility details.
Are foreign (non-U.S.) entities allowed to apply?
Yes. The opportunity allows non-U.S. (foreign) entities as eligible applicants, as described in the FOA's eligibility details.
Are small businesses eligible?
The eligibility list explicitly includes for-profit organizations other than small businesses, implying small businesses are not included in that category in the provided description.
What agency is issuing the announcement?
The announcement is issued by the NIH, specifically the National Cancer Institute (NCI).
What type of funding is this categorized as?
It is categorized as discretionary funding and uses a cooperative agreement instrument type.
What are the key dates for this announcement?
The announcement was posted on June 25, 2010. The original and current closing date was September 29, 2010. The archive date was October 30, 2010.
Is this opportunity still open?
No. Based on the listed closing date (September 29, 2010) and archive date (October 30, 2010), this specific FOA is not currently open.
What CFDA areas does this opportunity align with?
The announcement aligns with several cancer-related CFDA areas, including cancer cause and prevention research, detection and diagnosis research, cancer biology research, and cancer centers support grants.
Where can applicants find the official announcement and instructions?
The full announcement and official instructions were made available through the NIH Grants Guide at the link provided in the notice.
Browse more opportunities from the same category: Education Health
Next opportunity: DoD Peer Reviewed Orthopaedic Career Development Award
Previous opportunity: Moutain Goat Telemetry Project, Alaska
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 10 016
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 10 016) also looked into and applied for these:
| Funding Opportunity |
|---|
| Pre application for a Biomedical Technology Research Center (X02) Apply for PAR 10 224 Funding Number: PAR 10 224 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Biomedical Technology Research Center (P41) Apply for PAR 10 225 Funding Number: PAR 10 225 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Science Education Drug Abuse Partnership Award (R25) Apply for PAR 10 227 Funding Number: PAR 10 227 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Informatics, Coordination and Service Center for the Mutant Mouse Regional Resource Centers (U42) Apply for RFA RR 10 006 Funding Number: RFA RR 10 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Clinical Oncology Program Groups (U10) Apply for RFA CA 10 010 Funding Number: RFA CA 10 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Community Clinical Oncology Program Research Bases (U10) Apply for RFA CA 10 011 Funding Number: RFA CA 10 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Minority Based Community Clinical Oncology Program Groups (U10) Apply for RFA CA 10 012 Funding Number: RFA CA 10 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Clinical and Translational Science Coordinating Center (U54) Apply for RFA RR 10 007 Funding Number: RFA RR 10 007 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Health Promotion Among Racial and Ethnic Minority Males (R21) Apply for PA 10 237 Funding Number: PA 10 237 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Instrument Development for Biomedical Applications (R21) Apply for RFA RR 10 009 Funding Number: RFA RR 10 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $125,000 |
| Nutrition and Alcohol Related Health Outcomes (R01) Apply for PA 10 239 Funding Number: PA 10 239 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Nutrition and Alcohol Related Health Outcomes (R21) Apply for PA 10 241 Funding Number: PA 10 241 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| NIDA Program Project Grant Applications (P01) Apply for PAR 10 244 Funding Number: PAR 10 244 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Chimpanzee Biomedical Research Program Limited Competition (U42) Apply for RFA RR 10 008 Funding Number: RFA RR 10 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Data Coordinating Center (U10) Apply for RFA HL 11 028 Funding Number: RFA HL 11 028 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Core Clinical Centers (U10) Apply for RFA HL 11 013 Funding Number: RFA HL 11 013 Agency: National Institutes of Health Category: Education Health Funding Amount: $115,000 |
| Coordinating Center for the Barretts Esophagus Translational Research Network (U01) Apply for RFA CA 10 015 Funding Number: RFA CA 10 015 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Barretts Esophagus Translational Research Network (U54) Apply for RFA CA 10 014 Funding Number: RFA CA 10 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) Apply for RFA GM 11 003 Funding Number: RFA GM 11 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Neuroscience Research on Drug Abuse (R01) Apply for PA 10 268 Funding Number: PA 10 268 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 10 016", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.